1 Lakh
Investment Grown to₹ 10000
Monthly SIP Grown toSuitability:
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in multi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.
Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.
Taxability of earnings:
Capital gains
Dividends
Please wait...
Please wait...
| YTD | 1-Day | 1-W | 1-M | 3-M | 6-M | 1-Y | 3-Y | 5-Y | 7-Y | 10-Y | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | 41.74 | -0.59 | 1.52 | 13.75 | 20.67 | 33.16 | 56.17 | 19.84 | 8.95 | 18.59 | -- |
| S&P BSE Healthcare TRI | 40.53 | -0.32 | 2.64 | 15.44 | 24.81 | 32.13 | 50.60 | 11.33 | 2.03 | 12.04 | -- |
| Equity: Sectoral-Pharma | 43.46 | -0.13 | 2.76 | 15.22 | 22.56 | 33.72 | 56.80 | 15.21 | 6.15 | 16.28 | -- |
| Rank within category | 6 | 9 | 8 | 9 | 6 | 6 | 6 | 1 | 1 | 1 | -- |
| Number of funds in category | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 4 | 3 | 3 | 0 |
As on 07-Aug-2020
| Fund name | Rating | Launch Date | 1-Year Return | 3-Year Return | 5-Year Return | Expense Ratio | Assets (Cr) |
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan | Jan-13 | 56.17 | 19.84 | 8.95 | 1.35 | 3,093 | |
| ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan | Invest Now | Jul-18 | 58.97 | -- | -- | 1.37 | 1,523 | |
| SBI Healthcare Opportunities Fund - Direct Plan | Invest Online | Jan-13 | 56.77 | 11.19 | 4.15 | 1.23 | 1,154 | |
| Mirae Asset Healthcare Fund - Direct Plan | Invest Online | Jul-18 | 65.14 | -- | -- | 0.83 | 640 | |
| DSP Healthcare Fund - Direct Plan | Invest Online | Nov-18 | 69.19 | -- | -- | 1.04 | 571 |
| Best (Period) | Worst (Period) | |
|---|---|---|
| Week | 21.40 (01-Apr-2020 - 09-Apr-2020) | -12.21 (05-Mar-2020 - 12-Mar-2020) |
| Month | 38.63 (23-Mar-2020 - 22-Apr-2020) | -21.01 (20-Feb-2020 - 23-Mar-2020) |
| Quarter | 47.66 (23-Mar-2020 - 22-Jun-2020) | -14.04 (29-Dec-2015 - 29-Mar-2016) |
| Year | 67.54 (30-Sep-2013 - 30-Sep-2014) | -15.12 (08-Sep-2016 - 08-Sep-2017) |
| Mean | Std Dev | Sharpe | Sortino | Beta | Alpha | |
|---|---|---|---|---|---|---|
| Fund | 19.26 | 20.89 | 0.67 | 1.51 | 0.85 | 8.44 |
| S&P BSE Healthcare TRI | 11.82 | 23.98 | 0.28 | 0.67 | -- | -- |
| Equity: Sectoral-Pharma | 15.06 | 21.16 | 0.47 | 0.97 | 0.86 | 4.19 |
| Rank within category | 1 | 2 | 1 | 1 | 2 | 1 |
| Number of funds in category | 4 | 4 | 4 | 4 | 4 | 4 |
The Risk Measures have been calculated using calendar month returns for the last three years.
As on 31-Jul-2020
Please wait...
| Number of Stocks | 19 |
| Top 10 Stocks (%) | 77.42 |
| Top 5 Stocks (%) | 48.99 |
| Top 3 Sectors (%) | 98.07 |
| Portfolio P/B Ratio | 3.57 |
| Portfolio P/E Ratio | 32.88 |
| Fund | Category | |
|---|---|---|
| Average Mkt Cap (Rs Cr) | 31,119 | 28,993 |
| Giant (%) | 9.83 | 10.94 |
| Large (%) | 56.07 | 46.71 |
| Mid (%) | 22.95 | 27.43 |
| Small (%) | 11.15 | 14.92 |
| Tiny (%) | -- | -- |
Please wait...
| Company | Sector | P/E | 3Y High | 3Y Low | % Assets | |
|---|---|---|---|---|---|---|
|
Aurobindo Pharma | Healthcare | 18.77 | 11.96 | 5.49 | 10.48 |
|
Cipla | Healthcare | 35.69 | 11.10 | 5.81 | 9.94 |
|
|
Sun Pharmaceutical Inds. | Healthcare | 174.77 | 12.32 | 7.94 | 9.64 |
|
|
Dr. Reddy's Lab | Healthcare | 39.09 | 11.04 | 5.71 | 9.50 |
|
Lupin | Healthcare | -- | 9.43 | 3.33 | 9.43 |
|
|
Divi's Laboratories | Healthcare | 46.31 | 11.76 | 7.74 | 7.74 |
|
|
Syngene International | Healthcare | 47.41 | 7.15 | 0.00 | 6.35 |
|
|
Fortis Healthcare (India) | Healthcare | 179.76 | 6.89 | 0.00 | 5.68 |
|
|
Sanofi India | Healthcare | 42.33 | 10.26 | 4.46 | 4.46 |
|
|
Thyrocare Technologies | Healthcare | 60.45 | 7.24 | 3.63 | 4.20 |
|
|
Cadila Healthcare | Healthcare | 30.14 | 4.02 | 0.00 | 3.99 |
|
|
Biocon | Healthcare | 69.32 | 9.36 | 0.00 | 3.91 |
|
|
Abbott India | Healthcare | 52.41 | 11.05 | 3.57 | 3.57 |
|
|
Narayana Hrudayalaya | Healthcare | -- | 3.72 | 1.04 | 2.83 |
|
|
Alkem Laboratories | Healthcare | 26.13 | 6.36 | 0.11 | 2.38 |
|
|
Indoco Remedies | Healthcare | 93.20 | 2.50 | 0.00 | 2.14 |
|
|
Laurus Labs | Healthcare | 26.62 | 1.34 | 0.00 | 1.34 |
|
|
Healthcare Global Enterprises | Healthcare | -- | 3.72 | 0.26 | 0.42 |
|
Glaxosmithkline Pharma | Healthcare | 278.02 | 0.07 | 0.00 | 0.07 |
Indicates an increase or decrease or no change in holding since last portfolio
Indicates a new holding since last portfolio
As on 30-Jun-2020
— Sailesh Raj Bhan since 01-Jan-2013
Education: Mr. Bhan is an MBA (Finance) and CFA.
Experience: Mr. Sailesh Raj Bhan has about 19 years experience in equity research and fund management, with over 10 years at Reliance Nippon Life Asset Management Limited (formerly Reliance Capital Asset Management Limited). He manages diversified equity schemes like Reliance Equity Opportunities Fund (the largest Flexicap Scheme in India with assets of USD 800 million) since its inception in 2005 and Reliance Top200 Fund (a large cap diversified equity fund) since its inception in 2007. In addition, for over 9 years, he has been managing two specialized sector funds - Reliance Pharma Sector Fund (the largest pharma sector fund in India) and Reliance Media and Entertainment Fund.
Funds Managed:
Personal finance advice and mutual fund ideas delivered to your inbox every Monday
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
| Minimum Investment (₹) | 5,000 |
| Minimum Addl Investment (₹) | 1,000 |
| Minimum SIP Investment (₹) | 500 |
| Minimum No of Cheques | 60 |
| Minimum Withdrawal (₹) | 100 |
| Minimum Balance (₹) | 1 |
| Exit Load | 1% for redemption within 30 days |
| Fund House: | Nippon India Mutual Fund |
| Launch Date: | 01-Jan-2013 |
| Return Since Launch: | 16.86% |
| Benchmark: | S&P BSE Healthcare TRI |
| Riskometer: | High |
| Type: | Open-ended |
| Assets: | ₹ 3,093 Cr (As on 30-Jun-2020) |
| Expense: | 1.35% (As on 30-Jun-2020) |
| Risk Grade: | -- |
| Return Grade: | -- |
| Turnover: | 34.00% |
| Plan | Record Date | Dividend (₹ / Unit) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | 28-Feb-2020 | 3.9843 | |||||||||||||||||||||||||
| |||||||||||||||||||||||||||
AMC: Nippon India Life Asset Management Ltd.
Address: Reliance Centre, 7th Floor, South Wing Off Western Express Highway Santacruz (East) Mumbai - 400055
Phone: 022-68334800 / 18602660111
Fax: 022-33037662
Email: [email protected]
Website: http://www.nipponindiamf.com
Registrar & Transfer Agent: KFin Technologies Pvt Ltd.
Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016
Phone: 040-44857874
Email: [email protected]
Website: www.karvymfs.com
Friday, 14-Aug-2020
12:30 PM - 01:00 PM